324 related articles for article (PubMed ID: 34225811)
1. Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature.
Wang F; Liu Y; Xu W; Zhang C; Lv J; Ma S
J Med Case Rep; 2021 Jul; 15(1):336. PubMed ID: 34225811
[TBL] [Abstract][Full Text] [Related]
2. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
[TBL] [Abstract][Full Text] [Related]
3. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
[TBL] [Abstract][Full Text] [Related]
4. Fatal myocarditis after the first dose of nivolumab.
Zomborska E; Kasperova S; Slopovsky J; Pazderová N; Kasperova B; Penz P; Nyitrayová O; Salek T; Porsok S; Mladosievicova B; Mego M
Klin Onkol; 2022; 35(6):486-492. PubMed ID: 36513516
[TBL] [Abstract][Full Text] [Related]
5. Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report.
Hardy T; Yin M; Chavez JA; Ivanov I; Chen W; Nadasdy T; Brodsky SV
Cardiovasc Pathol; 2020; 46():107202. PubMed ID: 32062109
[TBL] [Abstract][Full Text] [Related]
6. [Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review].
Prevel R; Colin G; Calès V; Renault PA; Mazieres J
Rev Med Interne; 2020 Apr; 41(4):284-288. PubMed ID: 31983550
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report.
Delombaerde D; Vervloet D; Berwouts D; Beckers R; Prenen H; Peeters M; Gremonprez F; Croes L; Vulsteke C
J Med Case Rep; 2022 Jul; 16(1):275. PubMed ID: 35831829
[TBL] [Abstract][Full Text] [Related]
8. Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab.
Yamaguchi S; Morimoto R; Okumura T; Yamashita Y; Haga T; Kuwayama T; Yokoi T; Hiraiwa H; Kondo T; Sugiura Y; Watanabe N; Kano N; Kohno K; Fukaya K; Sawamura A; Yokota K; Ishii H; Nakaguro M; Akiyama M; Murohara T
Can J Cardiol; 2018 Jun; 34(6):812.e1-812.e3. PubMed ID: 29801747
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
10. Rapid Extracorporeal Membrane Oxygenation Overcomes Fulminant Myocarditis Induced by 5‑Fluorouracil.
Amraotkar AR; Pachika A; Grubb KJ; DeFilippis AP
Tex Heart Inst J; 2016 Apr; 43(2):178-82. PubMed ID: 27127440
[TBL] [Abstract][Full Text] [Related]
11. A rare case of nivolumab-related myasthenia gravis and myocarditis in a patient with metastatic gastric cancer.
Komatsu M; Hirai M; Kobayashi K; Hashidate H; Fukumoto J; Sato A; Usuda H; Tanaka K; Takahashi K; Kuwabara S
BMC Gastroenterol; 2021 Aug; 21(1):333. PubMed ID: 34445963
[TBL] [Abstract][Full Text] [Related]
12. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
Delasos L; Bazewicz C; Sliwinska A; Lia NL; Vredenburgh J
J Oncol Pharm Pract; 2021 Apr; 27(3):716-721. PubMed ID: 32723064
[TBL] [Abstract][Full Text] [Related]
13. An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer.
Naganuma K; Horita Y; Matsuo K; Miyama Y; Mihara Y; Yasuda M; Nakano S; Hamaguchi T
Intern Med; 2022 Oct; 61(19):2867-2871. PubMed ID: 35249925
[TBL] [Abstract][Full Text] [Related]
14. Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin.
Jain V; Mohebtash M; Rodrigo ME; Ruiz G; Atkins MB; Barac A
J Immunother; 2018 Sep; 41(7):332-335. PubMed ID: 29965858
[TBL] [Abstract][Full Text] [Related]
15. Drug reaction with eosinophilia and systemic symptoms syndrome associated myocarditis: a survival experience after extracorporeal membrane oxygenation support.
Lo MH; Huang CF; Chang LS; Kuo HC; Chien SJ; Lin IC; Lin KM; Lin YJ
J Clin Pharm Ther; 2013 Apr; 38(2):172-4. PubMed ID: 23173909
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists.
Frigeri M; Meyer P; Banfi C; Giraud R; Hachulla AL; Spoerl D; Friedlaender A; Pugliesi-Rinaldi A; Dietrich PY
Can J Cardiol; 2018 Jan; 34(1):92.e1-92.e3. PubMed ID: 29275889
[TBL] [Abstract][Full Text] [Related]
17. Keeping immune checkpoint inhibitor myocarditis in check: advanced circulatory mechanical support as a bridge to recovery.
Stein-Merlob AF; Hsu JJ; Colton B; Berg CJ; Ferreira A; Price MM; Wainberg Z; Baas AS; Deng MC; Parikh RV; Yang EH
ESC Heart Fail; 2021 Oct; 8(5):4301-4306. PubMed ID: 34390221
[TBL] [Abstract][Full Text] [Related]
18. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma.
Chen Q; Huang DS; Zhang LW; Li YQ; Wang HW; Liu HB
Clin Toxicol (Phila); 2018 Jul; 56(7):667-671. PubMed ID: 29126352
[TBL] [Abstract][Full Text] [Related]
19. Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review.
Chen Y; Jia Y; Liu Q; Shen Y; Zhu H; Dong X; Huang J; Lu J; Yin Q
Ann Palliat Med; 2021 Jul; 10(7):8512-8517. PubMed ID: 34263614
[TBL] [Abstract][Full Text] [Related]
20. Extracorporeal membrane oxygenation for the support of pediatric patients with acute fulminant myocarditis.
Şık G; Annayev A; Demirbuğa A; Deliceo E; Aydın S; Erek E; Demir Hİ; Çıtak A
Turk J Pediatr; 2019; 61(6):867-872. PubMed ID: 32134580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
